
The Agentic Clinical AI Regulatory Frontier: What ADVOCATE's $62.7M Contract Actually Unlocks
Dr. Dereck Mush, MD, MBAFDA cleared clinical AI that helps manage insulin treatment plans for people with type 2 diabetes.
UpDoc's FDA-cleared Software as a Medical Device uses patient-facing large language models, with initial deployments at four health systems. The company describes it as the first of its kind. Its AI agents support insulin treatment plan management within parameters set by the physician. In September 2026, ARPA-H awarded UpDoc up to $9.2 million under the ADVOCATE program to develop and validate an autonomous clinical AI system, starting in cardiovascular disease.
Leadership as of 14 November 2026.
How UpDoc got here, step by step.
25 June 2026
Announced FDA clearance for a Software as a Medical Device that uses patient-facing large language models, with initial deployments at four health systems (company-reported first of its kind).
9 September 2026
Awarded up to $9.2 million under ARPA-H's ADVOCATE program to develop and validate an autonomous clinical AI system, starting in cardiovascular disease.
9 September 2026
ARPA-H selects UpDoc under ADVOCATE25 June 2026
UpDoc announces FDA-cleared clinical AI platform
Dr. Dereck Mush, MD, MBA
Dr. Dereck Mush, MD, MBARelated companies
Your daily HealthTech Signal
Get the latest HealthTech news, understand why it matters, and see where the industry is headed.



Read by teams at companies like: